@misc{oai:repo.qst.go.jp:00064917,
 author = {大野, 達也 and 加藤, 真吾 and 若月, 優 and 唐澤, 久美子 and 中野, 隆史 and 辻井, 博彦 and 大野 達也 and 加藤 眞吾 and 若月 優 and 唐澤 久美子 and 辻井 博彦},
 month = {Nov},
 note = {(Purpose)
To evaluate the toxicity and efficacy of radiotherapy concurrently with weekly cisplatin follow-ed by adjuvant chemotherapy for N2-3 nasopharyngeal cancer.
\n(Materials and Methods)
Between 2005 and 2009, 121 patients with nasopharyngeal cancer (T1-4 N2-3 M0) were registered from Viet Nam, Malaysia, Indonesia, Thailand, The Philippines, China and Bangladesh. Patients were treated with 2-dimensional radiotherapy concurrently with weekly cisplatin (30mg/m2) followed by adjvant chemotherapy consisting of cisplatin (80mg/m2 on Day 1) and fluorouracil (800mg/m2 on Days 1_5) for three cycles.
\n(Results)
Ninety-three percent of the patients completed at least 4 cycles of weekly cisplatin during radiotherapy, and 82% completed at least 2 cycles of adjvant chemotherapy. Complete response was obtained in 95% of the patients. With a median follow-up time of 46 months for the survival, and overall survival rated were 75%, 65%, and 52%, respectively. No treatment-related deaths occurred. Grade 3-4 toxicities of mucositis, nausea/vomiing, and leukopenia were observed in 34% , 4%, and 4% of the patients, respectively.
\n(Conclusion)
The current results showed that concurrent chemoradiotherapy followed by adjuvant chemotherapy of our regimen was safe and effective in the participating institutes., 日本放射線腫瘍学会第25回学術大会},
 title = {Radiotherapy concurrently with weekly cisplatin followed by adjuvant chemotherapy for N2-3 nasopharyngeal cancer: Multicenter trial of the Forum for Nuclear Cooperation in Asia (FNCA)},
 year = {2012}
}